AIM Biotech is developing organ-on-a-chip technologies licensed from MIT for research, drug development and targeted therapeutics. AIM has a microfluidic cell culture platform for 3D organotypic models that has been used by over 100 labs in 18 countries, with publications in Nature Medicine, Cell, Cancer Cell, etc. Unique assays include immune checkpoint, T cell killing efficiency and blood-brain barrier. AIM’s modular platform is scalably manufactured with gas permeable materials that does away with the need for perfusion or rocking. The devices are designed to fit into existing lab & pharma workflows, using microplate & other established standards.